Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker

Oncology Reports

Volumn 21, Issue 1, 2009, Pages 95-100

  Hayashi, Tetsutaro ^a   Matsubara, Akio ^a   Ohara, Shinya ^a   Mita, Koji ^a   Hasegawa, Yasuhisa ^a   Usui, Tsuguru ^a   Arihiro, Koji ^b   Norimura, Shinichi ^a   Sentani, Kazuhiro ^a   Oue, Naohide ^a   Yasui, Wataru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Prostate cancer; Regenerating islet derived family member 4; Serum tumor marker

Indexed keywords

CHROMOGRANIN A; MUCIN 2; REGENERATING ISLET DERIVED FAMILY MEMBER 4; SYNAPTOPHYSIN; TUMOR MARKER; UNCLASSIFIED DRUG; LECTIN; MUC2 PROTEIN, HUMAN; REG4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; UROGENITAL TRACT CANCER; BIOSYNTHESIS; BLADDER TUMOR; BLOOD; KIDNEY TUMOR; MIDDLE AGED; PROSTATE TUMOR; UROGENITAL TRACT TUMOR; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CHROMOGRANIN A; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LECTINS, C-TYPE; MALE; MIDDLE AGED; MUCIN-2; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SYNAPTOPHYSIN; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 61449325195     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000194     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 57: 43-66, 2007.
2. Carter HB: Prostate cancers in men with low PSA levels - must we find them? N Engl J Med 350: 2292-2294, 2004.
3. Gambert SR: Prostate cancer. When to offer screening in the primary care setting. Geriatrics 56: 22-26, 2001.
4. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
5. Pantuck AJ, Zisman A, Rauch MK and Belldegrun A: Incidental renal tumors. Urology 56: 190-196, 2000.
6. Oue N, Hamai Y, Mitani Y, et al: Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 64: 2397-2405, 2004.
7. Aung PP, Oue N, Mitani Y, et al: Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 25: 2546-2557, 2006.
8. Hartupee JC, Zhang H, Bonaldo MF, Soares MB and Dieckgraefe BK: Isolation and characterization of a cDNA encoding a novel member of the human regenerating protein family: Reg IV. Biochim Biophys Acta 1518: 287-293, 2001.
9. Oue N, Mitani Y, Aung PP, et al: Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol 207: 185-198, 2005.
10. Oue N, Kuniyasu H, Noguchi T, et al: Serum concentration of Reg IV in patients with colorectal cancer: overexpression and high serum levels of Reg IV are associated with liver metastasis. Oncology 72: 371-380, 2007.
11. Takehara A, Eguchi H, Ohigashi H, et al: Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci 97: 1191-1197, 2006.
12. Gu Z, Rubin MA, Yang Y, et al: Reg IV: a promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res 11: 2237-2243, 2005.
13. Ohara S, Oue N, Matsubara A, et al: Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer. Cancer Sci (In press).
14. Mitani Y, Oue N, Matsumura S, et al: Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene 26: 4383-4393, 2007.
15. Sobin LH and Wittekind CH (eds): TNM Classification of Malignant Tumors, 6th edition. Wiley-Liss, New York, pp184-202, 2002.
16. Yasui W, Ayhan A, Kitadai Y, et al: Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas. Int J Cancer 53: 36-41, 1993.
17. Catalona WJ, Hudson MA, Scardino PT, et al: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 152: 2037-2042, 1994.
18. Rasmuson T, Grankvist K, Roos G and Ljungberg B: Neuroendocrine differentiation in renal cell carcinoma-evaluation of chromogranin A and neuron-specific enolase. Acta Oncol 38: 623-628, 1999.
19. Lau SK, Weiss LM and Chu PG: Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol 122: 61-69, 2004.
20. Mai KT, Perkins DG, Parks W, Rippstein P and Farmer J: Unusual immunostaining pattern of chromogranin in normal urothelium and in transitional cell neoplasms. Acta Histochem 96: 303-308, 1994.